title: TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells.
abstract: BACKGROUND
  Disseminated fibrosarcoma still represents a therapeutic dilemma because of lack of effective cytostatics. Therefore we tested tumor necrosis factor related apoptosis-inducing ligand (TRAIL) and taurolidine, in combination with established and new chemotherapeutic agents on human fibrosarcoma (HT1080).
  
  
  METHODS
  Human fibrosarcoma cells (HT1080) were incubated with doxorubicin, mafosfamide and trabectedin both alone and in combination with taurolidine and TRAIL. Vital, apoptotic and necrotic cells were quantified using flow cytometric analysis. Cell proliferation was analysed using a bromodeoxyuridine (BrdU) ELISA assay.
  
  
  RESULTS
  Single application of doxorubicin and trabectedin induced apoptotic cell death and significantly reduced the proliferation of HT1080 cells. In combination treatment, the addition of taurolidine and TRAIL resulted in a stronger reduction in the degree of cell viability when compared to single treatment. Trabectedin and taurolidine displayed a greater potential for inhibiting proliferation than did doxorubicin alone.
  
  
  CONCLUSIONS
  When combined with TRAIL and taurolidine, treatment with doxorubicin and trabectedin demonstrated stronger apoptosis-inducing and antiproliferative effects.
authors: Department of Hand and Plastic Surgery, Burn Centre, University Hospital Ludwigshafen, Ludwig-Guttmanstrasse 13, D-67071 Ludwigshafen, Germany. kamran.harati@t-online.de
authors: K
authors: K
authors: Harati
authors: A M
authors: AM
authors: Chromik
authors: D
authors: D
authors: Bulut
authors: O
authors: O
authors: Goertz
authors: S
authors: S
authors: Hahn
authors: T
authors: T
authors: Hirsch
authors: L
authors: L
authors: Klein-Hitpass
authors: M
authors: M
authors: Lehnhardt
authors: W
authors: W
authors: Uhl
authors: A
authors: A
authors: Daigeler
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D004149:Dioxoles / Q000008:administration & dosage / Q000494:pharmacology; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology; D004357:Drug Synergism; D005354:Fibrosarcoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000008:administration & dosage / Q000494:pharmacology; D013654:Taurine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000494:pharmacology; D013829:Thiadiazines / Q000008:administration & dosage / Q000494:pharmacology; D000077606:Trabectedin
chemical_list: D004149:Dioxoles; D011994:Recombinant Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D044005:Tetrahydroisoquinolines; D013829:Thiadiazines; D013654:Taurine; C048341:mafosfamide; D004317:Doxorubicin; D003520:Cyclophosphamide; C012566:taurolidine; D000077606:Trabectedin